At DeviceTalks Minnesota 2019, SPR Therapeutics founder, president & CEO Maria Bennett spoke with DeviceTalks program manager Sarah Faulkner about the company’s FDA-cleared peripheral nerve stimulation system for pain management. Want to see these interviews live? Join us at DeviceTalks West – Dec. 9-10 in Santa Clara, Calif. Sarah: Could you tell us a little […]
3M (NYSE:MMM) said yesterday that its board of directors nominated CEO Mike Roman as its new chairperson, with current exec chair Inge Thulin announcing their intention to retire. The move is slated to take effect following the St. Paul, Minn.-based company’s annual meeting of shareholders on May 14. “Under Inge’s leadership, 3M evolved into a more […]
SPR Therapeutics has raised $8 million of a $20 million Series C round of funding that began Jan. 19, according to an SEC filing. The Cleveland-based company’s Sprint peripheral nerve stimulation (PNS) system is FDA-cleared for both chronic and acute pain, including post-operative and post-traumatic pain. The product was launched in November 2018 with indications […]
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
SPR Therapeutics said today that it launched its FDA-cleared Sprint Endura single-lead peripheral nerve stimulation system intended for treating complex regional pain syndrome. Complex regional pain syndrome is a chronic pain condition affecting the limbs that can be caused by trauma, injury or surgery. The Cleveland-based company said that the device was used in its first […]
SPR Therapeutics said yesterday it received $10 million from two new grants and a contract from the US Dept. of Defense, all to support its percutaneous peripheral nerve stimulation therapy intended as a non-opioid pain relief therapy for both acute and chronic pain. The new awards bring the total number of grants and contracts the Cleveland, […]
The FDA has approved SPR Therapeutics’ (Cleveland) Sprint endura (single lead) and extensa (dual lead) peripheral nerve stimulation (PNS) systems. The minimally invasive Sprint system is the only FDA-approved percutaneous PNS system that is indicated for up to 60 days in the back and/or extremities for both chronic and acute pain and is the industry’s only dual lead […]
SPR Therapeutics said today it raised $25 million in a Series C round of financing to support commercialization and further research of its Sprint peripheral nerve stimulation system. The round was led by a “prominent family office” and Frontcourt Ventures, the Cleveland-based company said. As part of the funding, the company said it appointed former West […]
Pain management company SPR Therapeutics yesterday said it won FDA 510(k) clearance for its Sprint peripheral nerve stimulation system designed to provide chronic pain relief. The Cleveland, Ohio-based company touted the Sprint system as the 1st reversible and minimally-invasive PNS to win FDA clearance for treating chronic and acute pain, including post-operative and post-traumatic pain. […]
SPR Therapeutics touted a regulatory win across the pond for its Smartpatch peripheral nerve stimulation system for treating chronic shoulder pain as a result of stroke.
Cleveland, Ohio.-based SPR’s Smartpatch system is a "skin-mounted external stimulator" that can deliver up to 30-days of pain relief, according to a press release.